U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C72H101N17O26
Molecular Weight 1620.6735
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 13
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAPTOMYCIN

SMILES

CCCCCCCCCC(=N[C@@]([H])(Cc1c[nH]c2ccccc12)C(=N[C@]([H])(CC(=N)O)C(=N[C@@]([H])(CC(=O)O)C(=N[C@@]3([H])[C@@]([H])(C)OC(=O)[C@]([H])(CC(=O)c4ccccc4N)N=C([C@]([H])([C@]([H])(C)CC(=O)O)N=C([C@@]([H])(CO)N=C(CN=C([C@]([H])(CC(=O)O)N=C([C@@]([H])(C)N=C([C@]([H])(CC(=O)O)N=C([C@]([H])(CCCN)N=C(CN=C3O)O)O)O)O)O)O)O)O)O)O)O)O

InChI

InChIKey=DOAKLVKFURWEDJ-QCMAZARJSA-N
InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1

HIDE SMILES / InChI

Molecular Formula C72H101N17O26
Molecular Weight 1620.6735
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 13 / 13
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugbank.ca/drugs/DB00080

Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms. Daptomycin has a distinct mechanism of action, disrupting multiple aspects of bacterial cell membrane function. It inserts into the cell membrane in a phosphatidylglycerol-dependent fashion, where it then aggregates. The aggregation of daptomycin alters the curvature of the membrane, which creates holes that leak ions. This causes rapid depolarization, resulting in a loss of membrane potential leading to inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death. Daptomycin is bactericidal against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci, corynebacteria and stationary-phase Borrelia burgdorferi persisters.

CNS Activity

Curator's Comment:: Tissue distribution studies in rats have shown that daptomycin is retained in the kidney but appears to only minimally penetrate across the blood-brain barrier following single and multiple doses.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CUBICIN

Approved Use

CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2)

Launch Date

1.06332481E12
Curative
CUBICIN

Approved Use

CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2)

Launch Date

1.06332481E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
141.1 μg/mL
10 mg/kg 1 times / day steady-state, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
183.7 μg/mL
12 mg/kg 1 times / day steady-state, intravenous
dose: 12 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
57.8 μg/mL
4 mg/kg 1 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
93.9 μg/mL
6 mg/kg 1 times / day steady-state, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
123.3 μg/mL
8 mg/kg 1 times / day steady-state, intravenous
dose: 8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
59.1 ug/mL
6 mg/kg 1 times / day steady, intravenous
dose: 6 mg/kg
route of administration: intravenous
experiment type: steady
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: unhealthy
age: Adults
sex: F+M
food status:
92.3 ug/mL
8 mg/kg 1 times / day steady, intravenous
dose: 8 mg/kg
route of administration: intravenous
experiment type: steady
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: unhealthy
age: Adults
sex: F+M
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1039 μg × h/mL
10 mg/kg 1 times / day steady-state, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1277 μg × h/mL
12 mg/kg 1 times / day steady-state, intravenous
dose: 12 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
494 μg × h/mL
4 mg/kg 1 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
632 μg × h/mL
6 mg/kg 1 times / day steady-state, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
858 μg × h/mL
8 mg/kg 1 times / day steady-state, intravenous
dose: 8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
499 ug*h/mL
6 mg/kg 1 times / day steady, intravenous
dose: 6 mg/kg
route of administration: intravenous
experiment type: steady
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: unhealthy
age: Adults
sex: F+M
food status:
821 ug*h/mL
8 mg/kg 1 times / day steady, intravenous
dose: 8 mg/kg
route of administration: intravenous
experiment type: steady
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: unhealthy
age: Adults
sex: F+M
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.9 h
10 mg/kg 1 times / day steady-state, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.7 h
12 mg/kg 1 times / day steady-state, intravenous
dose: 12 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.1 h
4 mg/kg 1 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.9 h
6 mg/kg 1 times / day steady-state, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.3 h
8 mg/kg 1 times / day steady-state, intravenous
dose: 8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
8.5%
4 mg/kg 1 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DAPTOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg single, intravenous
Highest studied dose
Dose: 10 mg/kg
Route: intravenous
Route: single
Dose: 10 mg/kg
Sources:
unhealthy, 2 - 6 years
n = 6
Health Status: unhealthy
Condition: bacterial infection
Age Group: 2 - 6 years
Sex: M+F
Population Size: 6
Sources:
6 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 6 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 21 - 87 years
n = 120
Health Status: unhealthy
Condition: bacterial infection
Age Group: 21 - 87 years
Sex: M+F
Population Size: 120
Sources:
Disc. AE: Creatine kinase increased, Renal impairment...
AEs leading to
discontinuation/dose reduction:
Creatine kinase increased (3 patients)
Renal impairment (1 patient)
Death (18 patients)
Sources:
6 mg/kg single, intravenous
Recommended
Dose: 6 mg/kg
Route: intravenous
Route: single
Dose: 6 mg/kg
Sources:
unhealthy, 3–24 Months
Health Status: unhealthy
Condition: proven/suspected bacterial infection
Age Group: 3–24 Months
Sex: M+F
Sources:
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Co-administed with::
fosfomycin(2 g)
Sources:
unhealthy, 60.8 - 80.8 years
n = 74
Health Status: unhealthy
Condition: bacterial infection
Age Group: 60.8 - 80.8 years
Sex: M+F
Population Size: 74
Sources:
Disc. AE: Cardiac failure, Hypocalcemia...
AEs leading to
discontinuation/dose reduction:
Cardiac failure (4 patients)
Hypocalcemia (grade 4, 1 patient)
Acute renal failure (1 patient)
Acute liver injury (1 patient)
Gastrointestinal bleeding (1 patient)
Nausea and vomiting (2 patients)
Sources:
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 62 - 80 years
n = 81
Health Status: unhealthy
Condition: bacterial infection
Age Group: 62 - 80 years
Sex: M+F
Population Size: 81
Sources:
Disc. AE: Acute renal failure, Respiratory failure...
AEs leading to
discontinuation/dose reduction:
Acute renal failure (1 patient)
Respiratory failure (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Renal impairment 1 patient
Disc. AE
6 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 6 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 21 - 87 years
n = 120
Health Status: unhealthy
Condition: bacterial infection
Age Group: 21 - 87 years
Sex: M+F
Population Size: 120
Sources:
Death 18 patients
Disc. AE
6 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 6 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 21 - 87 years
n = 120
Health Status: unhealthy
Condition: bacterial infection
Age Group: 21 - 87 years
Sex: M+F
Population Size: 120
Sources:
Creatine kinase increased 3 patients
Disc. AE
6 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 6 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 21 - 87 years
n = 120
Health Status: unhealthy
Condition: bacterial infection
Age Group: 21 - 87 years
Sex: M+F
Population Size: 120
Sources:
Acute liver injury 1 patient
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Co-administed with::
fosfomycin(2 g)
Sources:
unhealthy, 60.8 - 80.8 years
n = 74
Health Status: unhealthy
Condition: bacterial infection
Age Group: 60.8 - 80.8 years
Sex: M+F
Population Size: 74
Sources:
Acute renal failure 1 patient
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Co-administed with::
fosfomycin(2 g)
Sources:
unhealthy, 60.8 - 80.8 years
n = 74
Health Status: unhealthy
Condition: bacterial infection
Age Group: 60.8 - 80.8 years
Sex: M+F
Population Size: 74
Sources:
Gastrointestinal bleeding 1 patient
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Co-administed with::
fosfomycin(2 g)
Sources:
unhealthy, 60.8 - 80.8 years
n = 74
Health Status: unhealthy
Condition: bacterial infection
Age Group: 60.8 - 80.8 years
Sex: M+F
Population Size: 74
Sources:
Nausea and vomiting 2 patients
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Co-administed with::
fosfomycin(2 g)
Sources:
unhealthy, 60.8 - 80.8 years
n = 74
Health Status: unhealthy
Condition: bacterial infection
Age Group: 60.8 - 80.8 years
Sex: M+F
Population Size: 74
Sources:
Cardiac failure 4 patients
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Co-administed with::
fosfomycin(2 g)
Sources:
unhealthy, 60.8 - 80.8 years
n = 74
Health Status: unhealthy
Condition: bacterial infection
Age Group: 60.8 - 80.8 years
Sex: M+F
Population Size: 74
Sources:
Hypocalcemia grade 4, 1 patient
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Co-administed with::
fosfomycin(2 g)
Sources:
unhealthy, 60.8 - 80.8 years
n = 74
Health Status: unhealthy
Condition: bacterial infection
Age Group: 60.8 - 80.8 years
Sex: M+F
Population Size: 74
Sources:
Acute renal failure 1 patient
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 62 - 80 years
n = 81
Health Status: unhealthy
Condition: bacterial infection
Age Group: 62 - 80 years
Sex: M+F
Population Size: 81
Sources:
Respiratory failure 1 patient
Disc. AE
10 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, 62 - 80 years
n = 81
Health Status: unhealthy
Condition: bacterial infection
Age Group: 62 - 80 years
Sex: M+F
Population Size: 81
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.
1989 Aug
Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats.
1990 Jan
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
2003 May
Muscle pain associated with daptomycin.
2004 Nov
Severe myopathy and possible hepatotoxicity related to daptomycin.
2005 Apr
Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
2005 Jan-Feb
Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.
2005 Oct
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
2006 Aug
Rhabdomyolysis and acute renal failure in a patient treated with daptomycin.
2006 Mar
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.
2006 Oct
Eosinophilic pneumonia induced by daptomycin.
2007 Apr
Therapy-refractory Panton Valentine Leukocidin-positive community-acquired methicillin-sensitive Staphylococcus aureus sepsis with progressive metastatic soft tissue infection: a case report.
2007 Dec 3
Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA).
2007 Jul
Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin.
2007 Nov
Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster.
2007 Nov 15
Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
2007 Oct
Daptomycin in the treatment of bacteremia.
2007 Oct
[New anti-Gram+antibiotics: which role in infective endocarditis?].
2008 Apr
Community-associated methicillin-resistant Staphylococcus aureus pyomyositis complicated by compartment syndrome in an immunocompetent young woman.
2008 Jul
Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis.
2008 May
Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy.
2008 May
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06.
2008 Nov
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.
2009 Apr
Successful salvage therapy with daptomycin after linezolid and vancomycin failure in a liver transplant recipient with methicillin-resistant Staphylococcus aureus endocarditis.
2009 Aug
Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
2009 Oct
Use of daptomycin in a pregnant patient with Staphylococcus aureus endocarditis.
2010 Apr
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").
2010 Aug
Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.
2010 Dec
Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.
2010 Feb 18
Successful medical treatment of bioprosthetic pulmonary valve endocarditis caused by methicillin-resistant Staphylococcus aureus.
2010 May
Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
2010 Nov
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).
2010 Nov
Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
2011 Jan
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

4 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min) 6 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min)
Route of Administration: Intravenous
In vitro activities of daptomycin was studied against more than 100 strains each of Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. For 392 of 421 strains (93%), daptomycin was inhibitory at <1 g/ml,
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:28:15 UTC 2021
Edited
by admin
on Fri Jun 25 21:28:15 UTC 2021
Record UNII
NWQ5N31VKK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DAPTOMYCIN
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
DAPTOMYCIN [MI]
Common Name English
LY-146032
Code English
CUBICIN
Brand Name English
CIDECIN
Brand Name English
DAPTOMYCIN [MART.]
Common Name English
DAPTOMYCIN [ORANGE BOOK]
Common Name English
DAPTOMYCIN [INN]
Common Name English
LY 146032
Code English
DAPTOMYCIN [WHO-DD]
Common Name English
DAPTOMYCIN [USAN]
Common Name English
DAPTOMYCIN [EMA EPAR]
Common Name English
LY-164032
Code English
N-DECANOYL-L-TRYPTOPHYL-L-ASPARAGINYL-L-ASPARTYL-L-THREONYLGLYCYL-L-ORNITHYL-L-ASPARTYL-D-ALANYL-L-ASPARTYLGLYCYL-D-SERYL-THREO-3-METHYL-L-GLUTAMYL-3-ANTHRANILOYL-L-ALANINE E1-LACTONE
Common Name English
DAPTOMYCIN [JAN]
Common Name English
DAPCIN
Brand Name English
DAPTOMYCIN [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175509
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
NDF-RT N0000175508
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
WHO-VATC QJ01XX09
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
NCI_THESAURUS C2363
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
EMA ASSESSMENT REPORTS CUBICIN (AUTHORIZED: ENDOCARDITIS, BACTERIAL)
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
WHO-ATC J01XX09
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
EMA ASSESSMENT REPORTS CUBICIN (AUTHORIZED: BACTEREMIA)
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
NDF-RT N0000175508
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
LIVERTOX 265
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
Code System Code Type Description
FDA UNII
NWQ5N31VKK
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
PUBCHEM
21585658
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
DRUG CENTRAL
783
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
EPA CompTox
103060-53-3
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
RXCUI
22299
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY RxNorm
LACTMED
Daptomycin
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
MESH
D017576
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
NCI_THESAURUS
C47470
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
DRUG BANK
DB00080
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
EVMPD
SUB06910MIG
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
WIKIPEDIA
DAPTOMYCIN
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL387675
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
CAS
103060-53-3
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
MERCK INDEX
M4093
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY Merck Index
INN
6127
Created by admin on Fri Jun 25 21:28:15 UTC 2021 , Edited by admin on Fri Jun 25 21:28:15 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> NON-INHIBITOR
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC